BioNTech (NASDAQ: BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

The "Global Cancer Vaccines Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's ...

Specialist cancer teams at Castle Hill Hospital in Cottingham are set to offer access to a personalised cancer vaccine for a ...

Medscape Medical News, June 30, 2023 BioNTech, OncoC4 Start Late-Stage Lung Cancer Drug Trial BioNTech and its US partner OncoC4 say they have started a late-stage study of their lung cancer ...

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

BioNTech has launched global clinical trials for BNT116, an mRNA vaccine designed to treat non-small cell lung cancer. Utilizing the same mRNA technology as Covid-19 vaccines, BNT116 aims to prime ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

“This is quite exciting,” said Dr. Shirish M. Gadgeel, a medical oncologist at the Henry Ford Cancer Institute in Detroit.